Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Feb. 6, 2026—Fujirebio and Sysmex have agreed on a sales collaboration in which Sysmex will exclusively sell Fujirebio’s fully automated Lumipulse immunoassay systems and reagents for dementia testing.
Feb. 5, 2026—The Food and Drug Administration has granted 510(k) clearance for Randox USA’s clinical drug testing panel.
Feb. 4, 2026—Congress passed yesterday a five-bill package called the Consolidated Appropriations Act of 2026, ending the partial government shutdown that began on Jan. 31.
Jan. 21, 2026—Zepto Life Technology has launched the FungiFlex Mold panel.
Jan. 28, 2026—Fujirebio launched the Lumipulse G pTau 217 CSF assay for the fully automated Lumipulse G immunoassay analyzers.
Jan. 27, 2026—Fujifilm Healthcare Americas Corp. and Voicebrook are partnering to integrate Voicebrook’s VoiceOver Pro with Fujifilm’s Synapse Pathology, a picture archiving and communication system designed to streamline case management.
Jan. 26, 2026—The Food and Drug Administration has approved Guardant Health’s Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with encorafenib (Braftovi, Pfizer) in combination with cetuximab and chemotherapy in accordance with the approved product labeling.
Jan. 13, 2026—Biocartis has entered into a research collaboration with Mayo Clinic to develop a rapid sample-to-answer test aiming to decrease the time to treatment for breast cancer patients.
Jan. 6, 2026—The American Medical Association has approved a new CPT proprietary laboratory analyses code for Personalized Medicine Care Diagnostics’ RenaDx, a comprehensive kidney genetics panel. The PLA code, 0628U, will become effective April 1.
Dec. 29, 2025—Diasorin has received FDA 510(k) clearance and CLIA waiver for its first assay, the Flu A/B, RSV and COVID-19 panel, to be used on the Liaison Nes point-of-care molecular diagnostic platform.
